Dropouts due to adverse events · adults (aged 18 and older) exposed to a traumatic event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
PTSD rate at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Functional disability at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity of PTSD symptoms ‐ Clinician‐rated · adults (aged 18 and older) exposed to a traumatic event
1 finding from 1 review
Dropouts due to adverse events · adults (aged 18 and older) exposed to a traumatic event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
PTSD rate at 3 months · adults (aged 18 and older) exposed to a traumatic event
It is very uncertain whether propranolol changes PTSD rate at 3 months compared with placebo (very low certainty).
1 finding from 1 review
Functional disability at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repetition of SH at post‐intervention · self‐harm in adults
It is very uncertain whether newer generation antidepressants (NGAs) changes repetition of SH by post‐intervention (NGA class)№ of participants:… compared with placebo (very low certainty).
3 findings from 1 review
OR 0.59 [0.29, 1.19]
Studies not reported
Very low
OR 0.67 [0.18, 2.41]
Studies not reported
Very low
OR 0.55 [0.24, 1.29]
Studies not reported
Low
Repetition of SH at post‐intervention · self‐harm in adults
Antipsychotics may leads to lower repetition of SH by post‐intervention№ of participants: 30(1 RCT) compared with placebo (low certainty).
1 finding from 1 review
OR 0.09 [0.02, 0.5]
Studies not reported
Low
Repetition of SH at post‐intervention · self‐harm in adults
Antipsychotics showed no clear difference in repetition of SH by post‐intervention№ of participants: 53(1 RCT) compared with another comparator drug or dose (low certainty).
1 finding from 1 review
OR 1.51 [0.5, 4.58]
Studies not reported
Low
Repetition of SH at post‐intervention · self‐harm in adults
It is very uncertain whether mood stabilisers, including antiepileptics and lithium changes repetition of SH by post‐intervention№ of participants: 167(1 RCT) compared with placebo (very low certainty).
1 finding from 1 review
OR 0.99 [0.33, 2.95]
Studies not reported
Very low
Repetition of SH at post‐intervention · self‐harm in adults
Natural products showed no clear difference in repetition of SH by post‐intervention№ of participants: 49(1 RCT) compared with placebo (low certainty).
1 finding from 1 review
OR 1.33 [0.38, 4.62]
Studies not reported
Low
Depressive symptoms · treatment‐resistant depression in adults
Switching to mianserin (60 mg/d) showed no clear difference in depressive symptoms (HAM‐D) Scale from: 0 to 54 (worse) compared with continuing on current antidepressant (fluoxetine 20 mg/d) (low certainty).
1 finding from 1 review
Quality of life ‐ not measured · treatment‐resistant depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depressive symptoms · treatment‐resistant depression in adults
1 finding from 1 review
Leaving the study early · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in dropouts compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).
1 finding from 1 review
Response (≥ 50% improvement in BDI‐II score) · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in response (≥ 50% improvement in BDI‐II score) compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).
1 finding from 1 review
Remission · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in remission (BDI‐II total score ≤ 9) compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).
1 finding from 1 review
Quality of life (EQ‐5D‐5L) ‐ 12 weeks · treatment‐resistant depression in adults
1 finding from 1 review